Fate Therapeutics Inc (FATE)

07:14 AM

Fate Therapeutics receives $15m CIRM grant for lupus trial By Investing.com - Investing.com Canada

07:14 AM

07:11 AM

Fate Therapeutics Receives $15 Million CIRM Grant to Advance Phase 2 RECLAIM-LN Trial of FT819 in Lupus Nephritis - quiverquant.com

07:11 AM

Sep 23, 2026

Fate Therapeutics Inc (F6T.MU) stock price, news, quote and history - Yahoo Finance UK

Sep 23, 2026

Sep 18, 2026

Longeveron slides 59% after-hours from stem cell therapy study failure - Mugglehead Investment Magazine

Sep 18, 2026

Sep 16, 2026

Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026 - GlobeNewswire

Sep 16, 2026

Sep 14, 2026

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of "Hold" by Analysts - MarketBeat

Sep 14, 2026

Sep 09, 2026

Fate Therapeutics presents FT819 lupus trial data at conference By Investing.com - Investing.com Nigeria

Sep 09, 2026

Sep 09, 2026

Fate Therapeutics at Cantor conference: autoimmune CAR-T push advances By Investing.com - Investing.com Canada

Sep 09, 2026

Sep 09, 2026

FATE: Scalable CAR T platform shows strong safety, efficacy, and promising phase II progress in lupus nephritis - TradingView

Sep 09, 2026

Sep 09, 2026

Fate Therapeutics to Present FT819 and FT839 Data at CCR West Meeting, Highlighting Safety and Efficacy in Autoimmune Disease - Quiver Quantitative

Sep 09, 2026

Sep 09, 2026

FATE News | FATE THERAPEUTICS INC (NASDAQ:FATE) - ChartMill

Sep 09, 2026

Sep 09, 2026

Fate Therapeutics Announces Encore Clinical Data - GlobeNewswire

Sep 09, 2026

Sep 08, 2026

Fate Therapeutics Market Sentiment - Benzinga España

Sep 08, 2026

Sep 06, 2026

FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials - Stocktwits

Sep 06, 2026

Sep 06, 2026

Fate Therapeutics (FATE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga España

Sep 06, 2026

Sep 04, 2026

Fate Therapeutics stock holds steady as investors watch cash runway and pipeline - ad-hoc-news.de

Sep 04, 2026

Sep 03, 2026

FATE Q2 2026 Earnings: Narrower Loss Beats Estimates as Clinical Pipeline Drives FocusPost-Earnings Drift - vinanet.vn

Sep 03, 2026

Sep 03, 2026

Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference - Yahoo Finance

Sep 03, 2026

Sep 03, 2026

BlackRock Inc. Makes New Investment in Fate Therapeutics, Inc. $FATE - MarketBeat

Sep 03, 2026

Sep 03, 2026

Fate Therapeutics stock stabilizes after autoimmune CAR-T safety shock - ad-hoc-news.de

Sep 03, 2026

Sep 02, 2026

Fate Therapeutics: RECLAIM-LN Underway, Additional Clinical Updates Ahead (NASDAQ:FATE) - Seeking Alpha

Sep 02, 2026

Aug 30, 2026

574,995 Shares in Fate Therapeutics, Inc. $FATE Acquired by Connor Clark & Lunn Investment Management Ltd. - MarketBeat

Aug 30, 2026

Aug 27, 2026

487,728 Shares in Fate Therapeutics, Inc. $FATE Acquired by Ieq Capital LLC - marketbeat.com

Aug 27, 2026

Aug 20, 2026

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat

Aug 20, 2026

Aug 17, 2026

Fate Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs

Aug 17, 2026

Aug 17, 2026

symbol__ Stock Quote Price and Forecast - CNN

Aug 17, 2026

Aug 16, 2026

Fate Therapeutics (FATE) Gains 1.98% to $2.57 as Stock Holds Above Key SupportStock News - dars.gov.et

Aug 16, 2026

Aug 16, 2026

Johnson & Johnson Makes New $9.12 Billion Investment in Fate Therapeutics, Inc. $FATE - MarketBeat

Aug 16, 2026

Aug 15, 2026

Fate Therapeutics (FATE) Rises 1.98% to $2.57 as it Approaches Key ResistanceAdvance Decline Line - vinanet.vn

Aug 15, 2026

Aug 15, 2026

Dimensional Fund Advisors LP Lowers Stock Holdings in Fate Therapeutics, Inc. $FATE - MarketBeat

Aug 15, 2026

Aug 14, 2026

Fate Therapeutics earnings beat by $0.02, revenue topped estimates - Investing.com Australia

Aug 14, 2026

Aug 14, 2026

Piper Sandler Maintains Fate Therapeutics(FATE.US) With Buy Rating, Raises Target Price to $8 - Moomoo

Aug 14, 2026

Aug 14, 2026

Fate Therapeutics Initiates Potentially Registrational Trial of Off-the-Shelf CAR T-Cell Therapy FT819 for Lupus Nephritis - BioPharm International

Aug 14, 2026

Aug 14, 2026

Fate Therapeutics Is Maintained at Equal-Weight by Wells Fargo - Moomoo

Aug 14, 2026

Aug 14, 2026

Wedbush Reaffirms "Outperform" Rating for Fate Therapeutics (NASDAQ:FATE) - MarketBeat

Aug 14, 2026

Aug 14, 2026

Fate Therapeutics doses first patient in FT819 lupus trial - Investing.com

Aug 14, 2026

Aug 14, 2026

Fate Therapeutics doses first patient in FT819 lupus trial By Investing.com - Investing.com Nigeria

Aug 14, 2026

Aug 14, 2026

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial Of FT819 For The Treatment Of Lupus Nephritis - TradingView

Aug 14, 2026

Aug 14, 2026

Fate Therapeutics Doses First Patient in Phase 2 RECLAIM-LN Trial of FT819 for Lupus Nephritis - Quiver Quantitative

Aug 14, 2026

Aug 14, 2026

Fate Therapeutics' First FT819 Patient Went Home Same Day - Stock Titan

Aug 14, 2026

Aug 14, 2026

FATE THERAPEUTICSPATIENTS TO RECEIVE SINGLE 900 MLN-CELL DOSE OF FT819; PRIMARY ENDPOINT AT WEEK 26 - webull.com

Aug 14, 2026

Aug 13, 2026

FATE THERAPEUTICS, INC. : WELLS FARGO RAISES TARGET PRICE TO $3.5 FROM $2.5 - Bitget

Aug 13, 2026

Aug 13, 2026

Fate Therapeutics (NASDAQ:FATE) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat

Aug 13, 2026

Aug 13, 2026

Fate Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 13, 2026

Aug 13, 2026

Fate Therapeutics, Inc. (FATE) Latest Stock News & Headlines - Yahoo! Finance Canada

Aug 13, 2026

Aug 13, 2026

Fate Therapeutics Reports Q2 2026 10-Q Filing Highlighting iPSC Pipeline and Key Risks - Kalkine Media

Aug 13, 2026

Aug 13, 2026

Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance

Aug 13, 2026

Aug 13, 2026

Form 8K Fate Therapeutics Inc For: 13 August By Investing.com - Investing.com Australia

Aug 13, 2026

Aug 13, 2026

Fate Therapeutics: Q2 Earnings Snapshot - marketscreener.com

Aug 13, 2026